Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.3701
Abstract: This Viewpoint discusses the findings of the Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial regarding the use of icosapent ethyl in moderate- to high-risk patients with fasting triglyceride levels greater than 135 mg/dL.
read more here.
Keywords:
icosapent ethyl;
icosapent;
cardiovascular prevention;
ethyl supplementation ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.48172
Abstract: Key Points Question What is the cost-effectiveness of icosapent ethyl from a US health care perspective for high-risk patients with hypertriglyceridemia despite statin treatment? Findings This economic evaluation including 8179 patients found that icosapent ethyl…
read more here.
Keywords:
risk patients;
icosapent ethyl;
cost;
high risk ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "American Heart Journal"
DOI: 10.1016/j.ahj.2021.01.018
Abstract: Objective: The MITIGATE study aims to evaluate the real-world clinical effectiveness of pre-treatment with icosapent ethyl (IPE), compared with usual care, on laboratory-confirmed viral upper respiratory infection (URI)-related morbidity and mortality in adults with established…
read more here.
Keywords:
risk;
risk adults;
cardiovascular risk;
icosapent ethyl ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2018 at "Nature Reviews Cardiology"
DOI: 10.1038/s41569-018-0129-2
Abstract: Nature reviews | C a r d i o l o g y Use of icosapent ethyl is associated with a reduction in triglyceride levels and ischaemic events, including cardiovascular death, according to the results…
read more here.
Keywords:
icosapent ethyl;
triglyceride levels;
ethyl;
risk ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2020 at "European Heart Journal"
DOI: 10.1093/ehjci/ehaa946.3341
Abstract: REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) randomized 8,179 statin-treated patients with elevated triglycerides and increased cardiovascular (CV) risk to either icosapent ethyl (IPE), a pure, stable prescription form of eicosapentaenoic acid, 4g/day…
read more here.
Keywords:
ldl changes;
statin type;
statin;
icosapent ethyl ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz778
Abstract: Abstract The aims of this clinical review are to: (i) highlight the importance of elevated baseline triglycerides (TG) in the setting of well-controlled low-density lipoprotein cholesterol (LDL-C) on statins as a major contributor to residual…
read more here.
Keywords:
trial;
events icosapent;
trial results;
profound reductions ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Current Opinion in Cardiology"
DOI: 10.1097/hco.0000000000000873
Abstract: Purpose of review Elevated levels of triglycerides, independent of low-density lipoprotein cholesterol (LDL-C) levels and statin therapy, are associated with heightened cardiovascular risk. Recent findings Mixed omega-3 fatty acid formulations, which contain varying amounts of…
read more here.
Keywords:
risk reduction;
icosapent ethyl;
risk;
cardiovascular risk ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Journal of Cellular and Molecular Medicine"
DOI: 10.1111/jcmm.15575
Abstract: The ω‐3 fatty acids exert as an antioxidant via the G protein‐coupled receptor 120 (GPR120). Icosapent ethyl, a purified eicosapentaenoic acid, showed a marked reduction in sudden cardiac death. Connexin43 is sensitive to redox status.…
read more here.
Keywords:
icosapent ethyl;
gpr120;
connexin43;
phosphorylation ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
0
Published in 2021 at "Open Heart"
DOI: 10.1136/openhrt-2021-001616
Abstract: Icosapent ethyl (Vascepa) is a purified preparation of the omega-3 fatty acid eicosapentaenoic acid, which is marketed by Amarin Pharma based in Ireland. The product was initially approved by the US Food and Drug Administration…
read more here.
Keywords:
ethyl;
ethyl scientific;
icosapent ethyl;
cardiovascular events ... See more keywords
Photo from wikipedia
Sign Up to like & get
recommendations!
1
Published in 2021 at "Circulation"
DOI: 10.1161/circulationaha.121.057464
Abstract: For decades, there has been interest in the role of omega-3 fatty acids (O3FAs) for the prevention of cardiovascular disease (CVD). Associations between fatty fish or O3FA consumption and lower incidences of CVD and mortality…
read more here.
Keywords:
fish oil;
oil supplements;
risk;
icosapent ethyl ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Stroke"
DOI: 10.1161/str.52.suppl_1.57
Abstract: Background: In patients at elevated cardiovascular risk, statins reduce the occurrence of ischemic stroke. However, residual stroke risk persists. Methods: REDUCE-IT, a multinational, double-blind ...
read more here.
Keywords:
ischemic stroke;
abstract reduction;
reduction ischemic;
stroke ... See more keywords